Captrust Financial Advisors lowered its position in CEL-SCI Co. (NYSEAMERICAN:CVM) by 22.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,483 shares of the company’s stock after selling 1,930 shares during the period. Captrust Financial Advisors’ holdings in CEL-SCI were worth $76,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. California Public Employees Retirement System grew its position in CEL-SCI by 4.8% during the 3rd quarter. California Public Employees Retirement System now owns 78,930 shares of the company’s stock worth $1,006,000 after purchasing an additional 3,600 shares during the last quarter. Ingalls & Snyder LLC purchased a new stake in CEL-SCI during the 4th quarter worth approximately $217,000. Swiss National Bank grew its position in CEL-SCI by 2.5% during the 4th quarter. Swiss National Bank now owns 83,000 shares of the company’s stock worth $968,000 after purchasing an additional 2,000 shares during the last quarter. ExodusPoint Capital Management LP purchased a new stake in CEL-SCI during the 3rd quarter worth approximately $196,000. Finally, Rhumbline Advisers grew its position in CEL-SCI by 6.7% during the 4th quarter. Rhumbline Advisers now owns 45,543 shares of the company’s stock worth $531,000 after purchasing an additional 2,842 shares during the last quarter. 30.03% of the stock is currently owned by hedge funds and other institutional investors.
NYSEAMERICAN:CVM opened at $16.29 on Thursday. The stock has a market cap of $660.22 million, a P/E ratio of -19.87 and a beta of 2.09. CEL-SCI Co. has a twelve month low of $10.37 and a twelve month high of $40.91. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.96 and a current ratio of 4.15. The stock’s 50 day moving average is $12.82.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
See Also: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding CVM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CEL-SCI Co. (NYSEAMERICAN:CVM).
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.